ValuEngine Upgrades BIONDVAX PHARMA/S (NASDAQ:BVXV) to Buy

ValuEngine upgraded shares of BIONDVAX PHARMA/S (NASDAQ:BVXV) from a hold rating to a buy rating in a research note issued to investors on Tuesday morning, ValuEngine reports.

Shares of NASDAQ:BVXV opened at $5.89 on Tuesday. The company has a market cap of $37.76 million, a P/E ratio of -1.64 and a beta of 1.15. BIONDVAX PHARMA/S has a 1 year low of $3.51 and a 1 year high of $7.26. The stock’s fifty day moving average price is $5.62 and its 200-day moving average price is $5.90.


BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which has completed Phase II clinical trials that is used for treating seasonal and pandemic strains of the influenza virus.

Read More: What is a Buy-Side Analyst?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for BIONDVAX PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIONDVAX PHARMA/S and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit